Subject Area: Ophthalmology

Selective laser trabeculoplasty in silicone oil-induced glaucoma

Hussam O. Elrashidy

Memorial Institute for Ophthalmic Research (MIOR), sarajaheen@gmail.com

Follow this and additional works at: https://jmisr.researchcommons.org/home

Part of the Medical Sciences Commons, and the Medical Specialties Commons

Recommended Citation

DOI: https://doi.org/10.4103/jmisr.jmisr_113_20

This Article is brought to you for free and open access by Journal of Medicine in Scientific Research. It has been accepted for inclusion in Journal of Medicine in Scientific Research by an authorized editor of Journal of Medicine in Scientific Research. For more information, please contact m_a_b200481@hotmail.com.
Abstract

Introduction
One of the complications of using silicone oil is glaucoma. Selective laser trabeculoplasty (SLT) became an increasingly focused laser procedure for glaucoma because of its efficacy and minimal destructive effects on the surrounding tissues. The aim of our study is to analyze the efficacy of SLT on silicone oil-induced secondary glaucoma in terms of intraocular pressure (IOP).

Patients and methods
This is prospective study on 30 eyes of 30 patients with silicone oil-induced secondary glaucoma. The patients should have had no history of glaucoma or ocular hypertension before silicone oil injection. The patients were treated with laser at 360° of the trabecular meshwork using Smart Selecta Duet Lumenis SLT, Germany.

Results
The baseline IOP ranged between 22 and 28 mmHg, with a mean IOP of 25 ± 2.0 mmHg. The IOP on the first day ranged between 20 and 26 mmHg, with a mean of 23 ± 1.5 mmHg. At first month, the range of IOP was 12–24 mmHg, with a mean of 18 ± 3 mmHg. At 3 months, it was 10–18 mmHg, with mean of 14 ± 3.8 mmHg. At 6 months, it was 11–20 mmHg, with a mean of 15 ± 4.2 mmHg (P = 0.01, 0.002, 0.003, and 0.004, respectively).

Conclusion
Our study suggested effectiveness of SLT in lowering the IOP in siliconized eyes with secondary glaucoma, and it is a safe procedure with no serious complications.

Keywords: Selective Laser Trabeculoplasty, Silicone oil induced glaucoma, SLT

INTRODUCTION
Silicone gel is an important adjunct in surgical treatment of retinal detachment as it is used as an endotamponade [1]. One of the complications of using silicone oil is glaucoma, and its incidence is difficult to ascertain. Some studies reported the rate of glaucoma from 2.2% in 6 months to 56% in 8 months [2,3]. Other studies reported incidence from 11 to 50% [4].

Many mechanisms of silicone oil-induced glaucoma include pupillary block, migration of emulsified and nonemulsified silicone oil to the anterior chamber blocking the trabecular meshwork, and inflammation inducing synechial angle closure [3,5,6].

Selective laser trabeculoplasty (SLT) became an increasingly focused laser procedure for glaucoma because of its efficacy and minimal destructive effects on the surrounding tissues [7]. SLT has also shown to be effective as primary treatment and adjunct to medical therapy [8].

AIM
The aim was to analyze the efficacy of SLT on silicone oil-induced secondary glaucoma in terms of intraocular pressure (IOP).

PATIENTS AND METHODS
This is prospective study on 30 eyes of 30 patients with silicone oil-induced secondary glaucoma. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Submitted: 17-Nov-2020 Revised: 13-Dec-2020 Accepted: 01-Jan-2021 Published: 19-May-2021

How to cite this article: Elrashidy HO. Selective laser trabeculoplasty in silicone oil-induced glaucoma. J Med Sci Res 2021;4:143-5.
We considered patients who cannot tolerate any topical antiglaucoma medications or who are not compliant with medical therapy. The patients should have had no history of glaucoma or ocular hypertension before silicone oil injection and at least 1 month with normal anterior chamber and anterior chamber angle on gonioscopy. We excluded patients with advanced field defects, previous glaucoma surgery, corneal disease that can interfere with accurate applanation measurements, patients on systemic steroids, or those who have uveitic glaucoma. The patients in this study were selected from patients undergoing retinal surgery with silicone oil injection. Immediately before the laser procedure, single application of proparacaine hydrochloride 0.5% was instilled into the eye. Then the patients were treated with laser at Smart Selecta Duet Lumenis SLT, Dreieich, Germany 360° of the trabecular meshwork using Smart Selecta Duet Lumenis SLT (Germany). The laser energy was initially set at 0.5 mJ and increased gradually by 0.1 mJ increment until bubble formation occurred. The treatment was continued on the minimal energy level for bubble formation. The entire meshwork was treated with 90–100 spots. Postoperatively, the patients were treated with fluorometholone 0.1%, and the same antiglaucoma medications used before treatment to avoid any IOP spikes. The patients were followed up for 6 months after treatment at 1 day after treatment, as well as 1, 3, and 6 months after laser. Postoperative examination included best-corrected visual acuity using Snellen’s chart, Goldmann’s applanation tonometry, slit-lamp biomicroscopy, and indirect ophthalmoscopy fundus examination. Data were presented in terms of parametric data. Parametric data were analyzed with analysis of variance and whenever appropriate with Student t test. All P values less than 0.05 were considered statistically significant. All statistical calculations were done using computer programs statistical package for social science (SPSS Inc., Chicago, Illinois, USA), version 18 for Microsoft Windows. The study followed the ethical values in collecting data, data analysis, and in keeping honesty. Informed consent was taken from the patients. All identifiable information about patients’ health status, medical condition, diagnosis, prognosis, treatment, and all other information of personal kind will be kept confidential.

**Results**

We analyzed the results of SLT in 30 eyes of 30 patients. The mean age of the patients was 55 years. Overall, 21 patients were males and nine patients were females. The underlying pathology that leads to vitreoretinal surgery with silicone oil injection was as follows:

1. Twelve eyes with rhegmatogenous retinal detachment.
2. Eight eyes with rhegmatogenous retinal detachment with proliferative vitreoretinopathy.
3. Six eyes with vitreous hemorrhage with proliferative vitreoretinopathy.
4. Four eyes with tractional retinal detachment and proliferative diabetic retinopathy.

All eyes had undergone pars-plana vitrectomy with silicone oil injection (22 eyes with silicone oil 5000 Centistoke and eight eyes with silicone oil 1000 Centistoke). Among the 30 patients, five patients were not on any medical treatment, 18 patients were on one medical treatment (carbonic anhydrase inhibitor), seven patients were on combination of carbonic anhydrase inhibitor and beta-blocker. A total of 23 patients were phakic and seven patients were aphakic. The laser energy used in the treatment were 0.5–0.7 mJ applied in 90–100 spots, including 180–360° of the angle of anterior chamber (Fig. 1 and Table 1).

The baseline IOP ranged between 22 and 28 mmHg, with a mean IOP of 25 ± 2.0 mmHg. The IOP at the first day ranged between 20 and 26 mmHg, with a mean of 23 ± 1.5 mmHg. At first month, the range of IOP was 12–24 mmHg, with a mean of 18 ± 3 mmHg. At 3 months, it was 10–18 mmHg, with a mean of 14 ± 3.8 mmHg. At 6 months, it was 11–20 mmHg, with a mean of 15 ± 4.2 mmHg (P = 0.01, 0.002, 0.003, and 0.004, respectively). No spikes were detected after SLT.

**Discussion**

Known complication of usage of silicone oil injection in case of vitrectomy is secondary glaucoma, which occurs postoperatively [1].

![Figure 1: The course of mean IOP during the follow-up period. IOP, intraocular pressure.](image)
Table 1: Patients’ characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of eyes</td>
<td>30</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>55</td>
</tr>
<tr>
<td>Male</td>
<td>21</td>
</tr>
<tr>
<td>Female</td>
<td>9</td>
</tr>
<tr>
<td>Pathology causing surgery</td>
<td></td>
</tr>
<tr>
<td>Rhegmatogenous RD</td>
<td>12</td>
</tr>
<tr>
<td>Rhegmatogenous RD+PDR</td>
<td>8</td>
</tr>
<tr>
<td>Vitreous hemorrhage+PDR</td>
<td>6</td>
</tr>
<tr>
<td>Tractional RD+PDR</td>
<td>4</td>
</tr>
<tr>
<td>Lens status</td>
<td></td>
</tr>
<tr>
<td>Phakic</td>
<td>23</td>
</tr>
<tr>
<td>Aphakic</td>
<td>7</td>
</tr>
<tr>
<td>Pre SLT Snellen BCVA</td>
<td></td>
</tr>
<tr>
<td>&gt;20/200</td>
<td>16</td>
</tr>
<tr>
<td>&lt;20/200 CF</td>
<td>10</td>
</tr>
<tr>
<td>HM</td>
<td>4</td>
</tr>
<tr>
<td>Number of antiglaucoma topical treatment before SLT</td>
<td></td>
</tr>
<tr>
<td>1 Medication</td>
<td>18</td>
</tr>
<tr>
<td>2 Medications</td>
<td>7</td>
</tr>
<tr>
<td>Not treated</td>
<td>5</td>
</tr>
<tr>
<td>Type of silicone oil used</td>
<td></td>
</tr>
<tr>
<td>1000 Centistoke</td>
<td>8</td>
</tr>
<tr>
<td>5000 Centistoke</td>
<td>22</td>
</tr>
<tr>
<td>SLT parameters</td>
<td></td>
</tr>
<tr>
<td>Number of laser spots</td>
<td>90-100</td>
</tr>
<tr>
<td>Degree of angle treated</td>
<td>180-360</td>
</tr>
</tbody>
</table>

BCVA, best-collected visual acuity; CF, counting fingers; HM, hand movement; PDR, proliferative diabetic retinopathy; RD, retinal detachment; SLT, selective laser trabeculoplasty.


The mechanisms of increased IOP in siliconeized eyes include excessive silicone injection, inflammation which can lead to synechial angle closure, and ruberosis iridis (these causes were not included in our study).

Open-angle glaucoma with obstruction of trabecular meshwork and Schlemm’s canal by migrated emulsified or nonemulsified silicone is the main cause of glaucoma [11,12]. This is confirmed by pathological examination, which proved that emulsified silicone drops or loaded macrophage can block the trabecular meshwork that leads to elevated IOP [13].

In our study, we chose cases with open-angle secondary glaucoma as detected with angle examination (Gonioscopy).

These patients whether on medical treatment (one or two medications) or not on medical treatment were treated with SLT, which induced significant reduction of IOP during the follow-up 6-month duration.

SLT induces reduction of IOP through the release of cytokines and chemotactic factors, which increase and upregulate macrophages in the trabecular meshwork [14]. Moreover, they increase the permeability of Schlemm’s canal cells [15].

In our study, there were no serious complications in using of SLT.

We have some limitations in our study, such as limited number of cases and follow-up duration.

**Conclusion**

In conclusion, our study suggested effectiveness of SLT in lowering the IOP in siliconized eyes with secondary glaucoma, and it is a safe procedure, with no serious complications.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**